Hypersensitivity to methylprednisolone. Note that there are no contraindications for the purpose of short-term large doses of the drug for health reasons.
Systemic application testoserone in doses exceeding those for replacement therapy is contraindicated in the following diseases and conditions:
– ulcers of the stomach and intestines;
– severe osteoporosis;
– mental disease history;
– Herpes simplex;
– Shingles (viremicheskaya stage)
– Chickenpox ;
– the period of 8 weeks prior to vaccination and two weeks after vaccination;
– amoebic infection;
– systemic mycosis,
– polio (except bulboentsefalitnoy form)
– lipoma, formed after testoseronevaccination;
– glaucoma (open-and-closure).
Urbazon soluble administered as part of combination therapy (compensation of circulating blood volume, the use of cardiotonic and vasopressor agents, antibiotics, analgesics). In acute adrenal insufficiency, syndrome shows the simultaneous use of mineralocorticoid.
Patients with underlying severe infectious and inflammatory diseases should be prescribed soluble only in conjunction with antibiotic therapy.
Care should be taken when appointing testoseronesoluble in patients with severe hypertension and chronic heart failure. It is necessary to ensure strict monitoring of the patients with diabetes mellitus: if necessary – to adjust the dose of antidiabetic drugs.
In pregnancy, and in case of a possible pregnancy, use of the drug is possible only for health reasons. If you want to carry out systemic treatment Urbazonom during the last weeks of pregnancy or during lactation, it should be remembered that methylprednisolone passes through the placenta and passes into breast milk. If during treatment a need arises to increase the dose, it is recommended to stop breast-feeding.
Use in children. Babies Urbazon not indicated, unless this is not a good reason.
When concomitant administration with cardiac glycosides may increase the action of cardiac glycosides under Urbazonom called hypokalemia. When concomitant administration with saluretikami may increase potassium excretion.
In a joint application with testoserone antidiabetic agents may decrease their hypoglycemic action, and when combined with coumarin derivatives – reducing their anticoagulant action.
When concomitant administration with rifampicin, phenytoin, barbiturates Urbazona efficiency may be reduced.
In a joint application Urbazona with nonsteroidal anti-inflammatory drugs increases the risk of gastrointestinal bleeding.
A solution of soluble incompatible with solutions of other drugs and infusion solutions (including a glucose solution).